Fennec Pharmaceuticals (NASDAQ: FENC), a specialty pharmaceutical company, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for PEDMARK™ (sodium thiosulfate), which was being developed as an intravenous administration for the prevention of ototoxicity...
Cogent Biosciences, Inc. (NASDAQ: COGT) is a clinical-stage biotechnology company targeting underlying causes of genetic dysfunction that cause diseases such as cancers, autoimmune disorders and rare diseases. The Company’s lead candidate bezuclastinib (CGT9486), is a precision kinase inhibitor that inhibits the KIT D816V mutation, which...
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical focused on creating novel therapies for treatment of cancer, announced that a crucial phase 3 trial of QINLOCK in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib did not meet the primary endpoint of improved...
